Drug intelligence / Profile preview

BioLink1006

Development stage: Unknown
Lead developer: Protheragen
Modality: Small Molecules
Administration: Oral

Overview

BioLink1006 is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) currently under development by Protheragen. It is positioned in Phase II clinical trials for the treatment of metastatic cancer. As an EGFR tyrosine kinase inhibitor (TKI), BioLink1006 is designed to bind to the intracellular kinase domain of EGFR, thereby blocking the downstream signaling pathways (such as RAS/MAPK and PI3K/AKT) that drive tumor cell proliferation and survival. The drug is part of Protheragen's portfolio of available projects for licensing and collaborative development.

Targets

EGFRvIII (Epidermal growth factor receptor variant III)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on BioLink1006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioLink1006.

Explore the full profile